Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $34,916.85 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the transaction, the insider now owns 164,363 shares of the company’s stock, valued at $2,292,863.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Trading Down 3.6 %

HIMS stock opened at $11.90 on Friday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16. The company has a fifty day simple moving average of $13.51 and a two-hundred day simple moving average of $9.84.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The business’s revenue for the quarter was up 47.4% on a year-over-year basis. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research reports. SVB Leerink initiated coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price for the company. Tigress Financial upped their target price on shares of Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Jefferies Financial Group restated a “hold” rating and set a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HIMS. CM Wealth Advisors LLC purchased a new position in Hims & Hers Health in the 2nd quarter worth about $25,000. Point72 Middle East FZE purchased a new position in Hims & Hers Health in the 4th quarter worth about $29,000. Captrust Financial Advisors increased its stake in Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after buying an additional 6,414 shares during the period. Harbour Investments Inc. increased its stake in Hims & Hers Health by 427.9% in the 3rd quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after buying an additional 5,670 shares during the period. Finally, Belpointe Asset Management LLC purchased a new position in Hims & Hers Health in the 1st quarter worth about $46,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.